Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
June 24, 2024 08:00 ET
|
Clene Inc.
SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
June 21, 2024 07:09 ET
|
Clene Inc.
CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental diseaseCNM-Au8 also demonstrated rescue of mitochondrial deficits in induced...
Clene to Present at the Emerging Growth Conference
June 05, 2024 08:00 ET
|
Clene Inc.
SALT LAKE CITY, June 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
May 28, 2024 07:30 ET
|
Clene Inc.
First patient, first visit is planned for early June 2024Enrollment has been expanded by 80% to a maximum of 180 participants‘Real-world’ drug efficacy data will be collected by monitoring potential...
Clene to Present at Upcoming May Conferences
May 14, 2024 08:00 ET
|
Clene Inc.
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
May 08, 2024 08:00 ET
|
Clene Inc.
Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from...
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
March 13, 2024 08:00 ET
|
Clene Inc.
Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label...